Analysen von Matthew Weston
| 04.09.25 | Roche Buy | UBS AG | |
| 01.09.25 | Novo Nordisk Neutral | UBS AG | |
| 29.08.25 | Novo Nordisk Neutral | UBS AG | |
| 29.08.25 | Novartis Neutral | UBS AG | |
| 27.08.25 | Sanofi Buy | UBS AG | |
| 22.08.25 | Novartis Neutral | UBS AG | |
| 19.08.25 | Novo Nordisk Neutral | UBS AG | |
| 14.08.25 | Bayer Neutral | UBS AG | |
|
Werbung
|
|||
| 12.08.25 | Novo Nordisk Neutral | UBS AG | |
| 07.08.25 | Merck Buy | UBS AG | |
| 06.08.25 | Bayer Neutral | UBS AG | |
| 06.08.25 | Novo Nordisk Neutral | UBS AG | |
| 05.08.25 | Novo Nordisk Neutral | UBS AG | |
| 29.07.25 | AstraZeneca Buy | UBS AG | |
| 22.07.25 | Sartorius vz. Neutral | UBS AG | |
| 14.07.25 | AstraZeneca Buy | UBS AG | |
| 03.07.25 | Novartis Neutral | UBS AG | |
| 16.06.25 | Roche Buy | UBS AG | |
| 16.06.25 | Novartis Neutral | UBS AG | |
| 06.06.25 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 29.04.25 | Novartis Neutral | UBS AG | |
| 29.04.25 | AstraZeneca Buy | UBS AG | |
| 25.04.25 | Merck Buy | UBS AG | |
| 25.04.25 | Roche Buy | UBS AG | |
| 24.04.25 | Roche Buy | UBS AG | |
| 17.04.25 | Sartorius vz. Neutral | UBS AG | |
| 16.04.25 | Sartorius vz. Neutral | UBS AG | |
| 14.04.25 | Roche Buy | UBS AG | |
| 10.04.25 | Novartis Neutral | UBS AG | |
| 10.04.25 | AstraZeneca Buy | UBS AG | |
| 09.04.25 | Novartis Neutral | UBS AG | |
| 07.04.25 | Roche Buy | UBS AG | |
| 01.04.25 | AstraZeneca Buy | UBS AG | |
| 17.03.25 | AstraZeneca Buy | UBS AG | |
| 12.03.25 | Roche Buy | UBS AG | |
| 12.03.25 | AstraZeneca Buy | UBS AG | |
| 12.03.25 | Merck Buy | UBS AG | |
| 10.03.25 | AstraZeneca Buy | UBS AG | |
| 10.03.25 | AstraZeneca Buy | UBS AG | |
| 07.03.25 | Merck Buy | UBS AG | |
| 06.03.25 | Merck Buy | UBS AG | |
| 27.02.25 | Merck Buy | UBS AG | |
| 21.02.25 | Roche Buy | UBS AG | |
| 13.02.25 | Novartis Neutral | UBS AG | |
| 13.02.25 | AstraZeneca Buy | UBS AG | |
| 06.02.25 | AstraZeneca Neutral | UBS AG | |
| 03.02.25 | Novartis Buy | UBS AG | |
| 31.01.25 | Novartis Buy | UBS AG | |
| 31.01.25 | Roche Neutral | UBS AG | |
| 30.01.25 | AstraZeneca Neutral | UBS AG | |